Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from RemeGen Co. Ltd. Class H ( (HK:9995) ).
RemeGen Co., Ltd. has approved a cash management plan allowing the use of up to RMB2.5 billion of idle self-owned funds and up to RMB80 million of idle A-share proceeds to purchase wealth management products. In line with this plan, the company has entered into seven agreements with the Yantai branch of Shanghai Pudong Development Bank between April 28 and May 13, 2026, committing a total of RMB1.43 billion into wealth management products, including RMB80 million from raised proceeds.
Because all the transactions were conducted with the same bank within a 12‑month period and are of a similar nature, they are aggregated under Hong Kong Listing Rules for classification purposes. The aggregated deal size triggers discloseable transaction status, meaning the purchases are subject to reporting and announcement requirements, highlighting RemeGen’s effort to enhance returns on idle funds while remaining within regulatory thresholds for such financial investments.
The most recent analyst rating on (HK:9995) stock is a Buy with a HK$129.00 price target. To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock, see the HK:9995 Stock Forecast page.
More about RemeGen Co. Ltd. Class H
RemeGen Co., Ltd. is a biopharmaceutical company incorporated in the People’s Republic of China and listed in Hong Kong under stock code 9995. The company operates in the life sciences and healthcare sector, focusing on the research, development and commercialisation of innovative therapies for various diseases in domestic and international markets.
Average Trading Volume: 4,178,519
Technical Sentiment Signal: Buy
Current Market Cap: HK$69.16B
See more data about 9995 stock on TipRanks’ Stock Analysis page.